1. Product advantages
High purity, all above 98.5%, no impurities after dissolution
We will test each batch to ensure quality
OEM and private brand services designed for free
Various cap colors available
We can also provide MT1 peptide powder
2. Factory advantages
Professional research team
More than 5 doctors in high-tech R&D laboratories
More than 1000 m2 of factory production line to ensure stable supply
More than 1200 factories to manufacture products and control quality
3. Service advantages
24-hour online service
Track package information and update it for customers
Professional sales team
Accept small order service
Redelivery service if detained by customs

Description: BAY 11-7085 is NF- κ B activation and I κ B α Phosphorylation inhibitor, stable I κ B α The IC50 value is 10 μ M.
Related categories
Signal pathway>>NF- κ B signaling pathway>>NF- κ B
Research field>>Cancer
Target points
NF- κ B
I κ B- α: ten μ M (IC50)
In vitro study on the inhibition of TNF by BAY 11-7085 α Induced E-selection proteins, surface expression of VCAM-1 and ICAM-1, with IC 50 values ranging from 5-10 μ Within the M range. BAY 11-7085 stabilizes I in a dose-dependent manner κ B α, The IC50 value is approximately 10 μ M. Stable I κ B α There is a significant correlation between the drug concentration, the concentration that inhibits the NF kB nuclear level, and the concentration that inhibits the expression of adhesion molecules [1]. BAY 11-7085 has been shown to inhibit cell proliferation and induce apoptosis in various cells. BAY 11-7085 (ECSCs) significantly inhibit cell proliferation and DNA synthesis of ovarian endometriotic cyst stromal cells, and induce apoptosis and G0/G1 phase cell cycle arrest in these cells. BAY 11-7085 induces ECSC apoptosis by inhibiting anti apoptotic proteins, and caspase-3, -8-, and -9 mediated cascades are involved in this mechanism [2].
In vivo studies have shown that BAY 11-7085 acts as an anti-inflammatory agent in rat carrageenan claw and adjuvant arthritis models. It demonstrated a dose-dependent reduction in swelling in the rat carrageenan claw model [1].
Cell experiments combined ECSC cells with BAY11-7085 (0.01-10) μ M) Incubate together for 48 hours. Afterwards, add 20 to each hole μ LWST-1 dye was used and the cells were further incubated for 4 hours. All experiments were conducted in the presence of 10% FBS. Evaluate cell proliferation by measuring absorbance at 540nm [2].
Animal experiment rats: Inject 0.1% carrageenan suspension in distilled water as 0.1mL of plantar fluid into the foot pad of the right hind paw and give it to the rats. One hour before injection, rats were intraperitoneally treated with a carrier (polyethylene glycol 400 diluted 1:5 in 5% bovine serum albumin/water) or a fine suspension of compound 2 (1,5 or 50mg/kg) in the carrier. It also includes a positive control group, in which rats were pretreated with 20mg/kg ibuprofen. Measure the volume of the injected claw 4 hours after administration of carrageenan. Determine the volume of edema .